arGEN-X advances a third therapeutic antibody program into preclinical development: http://t.co/hBB8aUOQ
posted 1 day ago
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
Ablynx [Euronext Brussels: ABLX], announced today that it has been awarded a grant worth €1.1 million by the Flemish agency for Innovation by Science and Technology (IWT).
The grant allows Ablynx to accelerate its development of alternative routes of administration for therapeutic Nanobodies, and build on the successes that have been achieved so far in this area.
In December 2008, Ablynx concluded its first feasibility study of pulmonary delivery and demonstrated in vivo that anti-viral Nanobodies protect against viral infection and eliminate active virus when delivered via an intra-pulmonary route. Ablynx has also demonstrated that Nanobody administration via the lungs resulted in up to 10 times longer systemic exposure compared with intravenous administration.
Ablynx will use the grant to accelerate the development of pulmonary and oral delivery technologies for its Nanobodies. The Company will continue to explore several other potential routes including topical and ocular administration.
Edwin Moses, CEO and Chairman of Ablynx, said: “We are very pleased with IWT’s continued support of Ablynx’s Nanobody technology platform. This grant will allow us to continue to investigate alternative routes of administration for our therapeutic Nanobodies which could result in considerable benefits for patients. Advances in this area could significantly impact on a number of our therapeutic programmes and open up more exciting new opportunities for Ablynx and its partners.”
Source: Ablynx
Tags: financing
Bookmark this:
